Exhibit 99.1 Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance -- Generated 52.5millioninnetrevenuefromsalesofLUMRYZ™,a9352.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate 52.5millioninnetrevenuefromsalesofLUMRYZ™,a93255 - 265millioninnetproductrevenueandcashflowof265 million in net product revenue and cash flow of 265millioninnetproductrevenueandcashflowof30 - $40 million, ...
Avadel Pharmaceuticals plc(US:AVDL)2025-05-07 19:07